These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 10588085)

  • 1. Modeling the impact of subclinical measles transmission in vaccinated populations with waning immunity.
    Mossong J; Nokes DJ; Edmunds WJ; Cox MJ; Ratnam S; Muller CP
    Am J Epidemiol; 1999 Dec; 150(11):1238-49. PubMed ID: 10588085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence of vaccine-induced antibody to measles 26-33 years after vaccination.
    Dine MS; Hutchins SS; Thomas A; Williams I; Bellini WJ; Redd SC
    J Infect Dis; 2004 May; 189 Suppl 1():S123-30. PubMed ID: 15106101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of subclinical infection on maintaining immunity against measles in vaccinated children in West Africa.
    Whittle HC; Aaby P; Samb B; Jensen H; Bennett J; Simondon F
    Lancet; 1999 Jan; 353(9147):98-102. PubMed ID: 10023894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance of recent measles virus wild-type isolates to antibody-mediated neutralization by vaccinees with antibody.
    Klingele M; Hartter HK; Adu F; Ammerlaan W; Ikusika W; Muller CP
    J Med Virol; 2000 Sep; 62(1):91-8. PubMed ID: 10935994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measles antibody in vaccinated human immunodeficiency virus type 1-infected children.
    Arpadi SM; Markowitz LE; Baughman AL; Shah K; Adam H; Wiznia A; Lambert G; Dobroszycki J; Heath JL; Bellini WJ
    Pediatrics; 1996 May; 97(5):653-7. PubMed ID: 8628602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Waning immunity and subclinical measles infections in England.
    Glass K; Grenfell BT
    Vaccine; 2004 Sep; 22(29-30):4110-6. PubMed ID: 15364464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating age-specific vaccine effectiveness using data from a large measles outbreak in Berlin, Germany, 2014/15: evidence for waning immunity.
    Bitzegeio J; Majowicz S; Matysiak-Klose D; Sagebiel D; Werber D
    Euro Surveill; 2019 Apr; 24(17):. PubMed ID: 31039834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term waning of vaccine-induced immunity to measles in England: a mathematical modelling study.
    Robert A; Suffel AM; Kucharski AJ
    Lancet Public Health; 2024 Oct; 9(10):e766-e775. PubMed ID: 39342948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Waning antibodies in measles and rubella vaccinees--a longitudinal study.
    Kremer JR; Schneider F; Muller CP
    Vaccine; 2006 Mar; 24(14):2594-601. PubMed ID: 16427163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of plaque reduction neutralisation test (PRNT) and measles virus-specific IgG ELISA for assessing immunogenicity of measles vaccination.
    Cohen BJ; Doblas D; Andrews N
    Vaccine; 2008 Nov; 26(50):6392-7. PubMed ID: 18834911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An increasing, potentially measles-susceptible population over time after vaccination in Korea.
    Kang HJ; Han YW; Kim SJ; Kim YJ; Kim AR; Kim JA; Jung HD; Eom HE; Park O; Kim SS
    Vaccine; 2017 Jul; 35(33):4126-4132. PubMed ID: 28669617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Waning of vaccine-induced immunity: is it a problem in Africa?
    Aaby P; Cisse B; Simondon F; Samb B; Soumaré M; Whittle H
    Am J Epidemiol; 1999 Feb; 149(4):304-5. PubMed ID: 10025471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A long-term follow-up study on the efficacy of further attenuated live measles vaccine, Biken CAM vaccine.
    Isomura S; Morishima T; Nishikawa K; Hanada N; Rahman M; Terashima M; Kido S; Ueda S; Takahashi M
    Biken J; 1986 Mar; 29(1):19-26. PubMed ID: 3778422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laboratory characterization of measles virus infection in previously vaccinated and unvaccinated individuals.
    Hickman CJ; Hyde TB; Sowers SB; Mercader S; McGrew M; Williams NJ; Beeler JA; Audet S; Kiehl B; Nandy R; Tamin A; Bellini WJ
    J Infect Dis; 2011 Jul; 204 Suppl 1():S549-58. PubMed ID: 21666212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measles vaccine immunogenicity in 6- versus 15-month-old infants born to mothers in the measles vaccine era.
    Johnson CE; Nalin DR; Chui LW; Whitwell J; Marusyk RG; Kumar ML
    Pediatrics; 1994 Jun; 93(6 Pt 1):939-44. PubMed ID: 8190581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anti-measles humoral immunity in children with thymus hyperplasia].
    Gurvich EB; Lysenkova NV; Shishatskaia SN; Vaganov PD; Ozeretskovskiĭ NA
    Pediatriia; 1989; (9):31-3. PubMed ID: 2587164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative analysis of titers of antibody against measles virus in sera of vaccinated and naturally infected Japanese individuals of different age groups.
    Itoh M; Okuno Y; Hotta H
    J Clin Microbiol; 2002 May; 40(5):1733-8. PubMed ID: 11980952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seroprevalence of neutralizing antibodies to measles virus in a vaccinated population in Iran, 1998.
    Loo MK; Sabahi F; Soleimanjdahi H; Kazemnejad A; Roustai MH
    Eur J Epidemiol; 2003; 18(11):1085-9. PubMed ID: 14620944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measles epidemic in Romania, 1996-1998: assessment of vaccine effectiveness by case-control and cohort studies.
    Hennessey KA; Ion-Nedelcu N; Craciun MD; Toma F; Wattigney W; Strebel PM
    Am J Epidemiol; 1999 Dec; 150(11):1250-7. PubMed ID: 10588086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modelling antibody response to measles vaccine and subsequent waning of immunity in a low exposure population.
    Mossong J; O'Callaghan CJ; Ratnam S
    Vaccine; 2000 Oct; 19(4-5):523-9. PubMed ID: 11027817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.